

NOTE: This disposition is nonprecedential.

**United States Court of Appeals  
for the Federal Circuit**

---

**AMGEN INC., AMGEN MANUFACTURING,  
LIMITED,**  
*Appellants*

v.

**KATHERINE K. VIDAL, UNDER SECRETARY OF  
COMMERCE FOR INTELLECTUAL PROPERTY  
AND DIRECTOR OF THE UNITED STATES  
PATENT AND TRADEMARK OFFICE,**  
*Intervenor*

---

2019-2171

---

Appeal from the United States Patent and Trademark  
Office, Patent Trial and Appeal Board in No. IPR2016-  
01542.

---

Decided: April 14, 2022

---

ARLENE L. CHOW, Latham & Watkins LLP, New York,  
NY, for appellants. Also represented by JON STEVEN  
BAUGHMAN, Paul, Weiss, Rifkind, Wharton & Garrison  
LLP, Washington, DC; JENNIFER GORDON, NICHOLAS P.  
GROOMBRIDGE, New York, NY.

THOMAS W. KRAUSE, Office of the Solicitor, United States Patent and Trademark Office, Alexandria, VA, for intervenor. Also represented by AMY J. NELSON; MAUREEN DONOVAN QUELER.

---

Before CHEN, SCHALL, and STOLL, *Circuit Judges*.

CHEN, *Circuit Judge*.

Appellants Amgen Inc. and Amgen Manufacturing Ltd. (collectively, Amgen) appeal a Final Written Decision and reconsideration of the same by the Patent Trial and Appeal Board (Board) in an *inter partes* review proceeding involving U.S. Patent No. 8,952,138 ('138 patent). The Board determined that claims 1–24 of the '138 patent are unpatentable under 35 U.S.C. § 103(a). Amgen appeals the Board's construction of the claim term "final thiol-pair ratio" and determination that claims 1–24 are unpatentable. For the following reasons, we *reverse*.

#### BACKGROUND

The '138 patent explains that when recombinant proteins are formed in non-mammalian expression systems (e.g., bacterial cells), they can precipitate into limited-solubility aggregates of misfolded proteins called "inclusion bodies." '138 patent at col. 1 ll. 20–24. To obtain properly folded proteins from inclusion bodies, practitioners developed various methods to accomplish refolding. *Id.* at col. 1 ll. 36–38. Such methods generally include steps of (1) extracting the inclusion bodies from the expression system; (2) solubilizing the inclusion bodies in a solubilization buffer, which disassembles the inclusion bodies into individual protein chains and unfolds the proteins; and (3) diluting or washing the unfolded proteins in a refolding buffer, which causes the proteins to refold in the proper manner. *Id.* col. 1 ll. 38–51.

The '138 patent claims methods for refolding proteins at high concentrations using a controlled reduction-oxidation (redox) reaction. See '138 patent at claims 1–24; see also *id.* at col. 1 ll. 11–14, col. 2 ll. 52–61. Claim 1 is the only independent claim, and claims 2–24 depend therefrom.

In its Final Written Decision, the Board construed “final thiol-pair ratio,” recited in claim 1, to mean “the relationship of the reduced and oxidized redox species used in the redox component of the refold buffer as defined by the [following] equation”:

$$\frac{[\text{reductant}]^2}{[\text{oxidant}]}$$

*Apotex Inc. v. Amgen Inc.*, IPR2016-01542, 2018 WL 935620, at \*4 (P.T.A.B. Feb. 15, 2018) (*Final Written Decision*). Based on this construction of “final thiol-pair ratio,” the Board determined that Petitioners Apotex Inc. and Apotex Corp. (collectively, Apotex) had demonstrated that claim 1 is unpatentable over Schlegl<sup>1</sup> in view of Hevehan.<sup>2</sup> J.A. 40–47, 62. Since Amgen did not separately argue the patentability of dependent claims 2–17 and 19–24, the Board concluded claims 2–17 and 19–24 are also unpatentable. J.A. 47–55, 58–60. Although the Board was initially unpersuaded that Apotex had demonstrated that claim 18 was unpatentable, the Board later reconsidered and amended its *Final Written Decision* to find claim 18 unpatentable. *Apotex Inc. v. Amgen Inc.*, No. IPR2016-01542, 2019 WL 2180042, at \*5–6 (P.T.A.B. May 20, 2019); see also *Final Written Decision*, at \*18.

---

<sup>1</sup> U.S. Patent Pub. No. 2007/0238860. J.A. 248–60.

<sup>2</sup> Diane L. Hevehan & Eliana De Bernardez Clark, *Oxidative Renaturation of Lysozyme at High Concentrations*, 54 *Biotechnology & Bioengineering* 221 (1997). J.A. 261–270.

Amgen appeals the Board's construction of "final thiol-pair ratio" and unpatentability determinations based on the same. Apotex informed this Court that it would not participate in the appeal, ECF No. 2, and the U.S. Patent and Trademark Office (Patent Office) intervened to defend the Board's decision, ECF No. 11. We have jurisdiction under 28 U.S.C. § 1295(a)(4)(A).

## DISCUSSION

### A

Because Apotex filed its petition for *inter partes* review before November 13, 2018, we apply the broadest reasonable interpretation claim construction standard. *Valve Corp. v. Ironburg Inventions Ltd.*, 8 F.4th 1364, 1380 n.14 (Fed. Cir. 2021). There being no dispute here about findings or evidence of facts extrinsic to the patent, we conduct a de novo review of the Board's determination of the broadest reasonable interpretation of the claim language. *See In re Cuozzo Speed Techs., LLC*, 793 F.3d 1268, 1279–80 (Fed. Cir. 2015); *Microsoft Corp. v. Proxycorr, Inc.*, 789 F.3d 1292, 1297 (Fed. Cir. 2015).

Obviousness is a question of law based on underlying factual determinations. *Facebook, Inc. v. Windy City Innovations, LLC*, 973 F.3d 1321, 1339 (Fed. Cir. 2020). We review the Board's legal conclusions de novo and its factual findings for substantial evidence. *ACCO Brands Corp. v. Fellowes, Inc.*, 813 F.3d 1361, 1365 (Fed. Cir. 2016).

### B

Amgen argues the Board misconstrued "final thiol-pair ratio" because claim 1's "language makes clear that the redox component is a distinct volume from the refold buffer, and it is that *redox component* [rather than the refold buffer] that comprises the claimed 'final thiol-pair ratio.'" *See* Appellant's Br. 41–42, 43. Since the thiol-pair ratio (TPR) equation is volume-dependent, the TPR value will be different when calculated in the redox component versus

the refold buffer. *Id.* at 40–41, 43–44. The Patent Office responds that redox component is not, and need not be, a separate volume from the refold buffer. Intervenor’s Br. 36–37. The Patent Office assumes that the only way to give meaning to the word “final” in “final thiol-pair ratio” and make sense of the ’138 patent’s claims and specification is to understand “final thiol-pair ratio” in the context of the ultimate solution—i.e., the refold mixture—rather than specific ingredients therein—e.g., the redox component. *Id.* at 38–39. We agree with Amgen.

Claim 1 recites “contacting the protein with a refold buffer comprising a redox component comprising a final thiol-pair ratio. . . . to form a refold mixture.” ’138 patent at claim 1. A straightforward reading of the claim language indicates that the “final thiol-pair ratio” is an attribute of the redox component. *Id.* Additionally, the ’138 patent specification distinguishes between “final thiol-pair ratio,”<sup>3</sup> “buffer thiol-pair ratio,”<sup>4</sup> and “system thiol-pair ratio,”<sup>5</sup> which respectively correspond to TPR values calculated in the “redox component,” “refold buffer,” and “refold

---

<sup>3</sup> “In various embodiments the *redox component* has a final thiol-pair ratio.” ’138 patent at col. 2 ll. 62–64 (emphasis added); *see also id.* at col. 8 ll. 37–43, col. 9 ll. 20–22, col. 10 ll. 22–26, col. 11 ll. 9–13 & 40–42 & 54–63, col. 13 ll. 29–35.

<sup>4</sup> “As used herein, the term ‘buffer thiol-pair ratio’ is defined by the relationship of the reduced and oxidized redox species used in the *refold buffer* as defined in Equation 1[.]” *Id.* at col. 6 ll. 20–28 (emphasis added); *see also id.* at col. 4 ll. 39–42 & ll. 46–48, col. 10 ll. 45–56.

<sup>5</sup> “The buffer thiol-pair ratio is, however, only one component in determining the total system thiol-pair ratio in the *total reaction*.” *Id.* at col. 4 ll. 46–48 (emphasis added); *see also id.* at col. 4 ll. 48–51 & 55–58, col. 9 ll. 3–13.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.